Huasen Pharmaceuticals: Subsidiary obtains approval notice for innovative drug clinical trial.

Huasen Pharmaceuticals announced that its subsidiary, Chongqing Huasen Yino Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the issuance of two specifications of the "Drug Clinical Trial Approval Notice" for HSN002066C1 tablets. HSN002066C1 tablets are a selective polyphosphate adenosine-ribonucleic acid polymerase 7 small molecule inhibitor independently developed by Huasen Yino with complete proprietary intellectual property rights, and are clinically intended for the treatment of advanced malignant solid tumors via oral administration.